Clinical trials: Alcohol-Related Liver Disease
Alcoholic Liver Disease
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
Recent years, the European Association for the Study of the Liver-chronic liver failure (EASL-CLIF) has defined and graded acute-on-chronic liver failure (ACLF) based on CANONIC study which enrolled cirrhotic patients with acute…
- Trial name
- SCALE (NCT03295812)
- Testing
- standard therapy
- Where
- 26 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Alcoholic Hepatitis, Acute Liver Failure
Outcomes Using MARS for Patients With ALF
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival…
- Trial name
- NCT05594953
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Methodist Health System
Alcohol Use Disorder, HIV/AIDS
Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
Among patients with HIV, especially those also infected with HCV, heavy drinking is associated with significant risks to health.
- Conditions
- Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
- Trial name
- NCT03652675
- Testing
- Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- New York State Psychiatric Institute
Alcohol-related Liver Disease
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease.
- Trial name
- NCT06409130
- Testing
- NNC0194-0499, Semaglutide, Cagrilintide + semaglutide
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Transplant; Failure, Liver, Addiction, Alcohol
Addiction Intervention in Liver Transplantation Candidates
Addiction care is "a la carte treatment", adapted to the motivation and time constrains of users. Thus, various types of psychotherapeutic follow-up can be considered, different addictolytic medications or opioid maintenance…
- Trial name
- Addictolive (NCT05322226)
- Testing
- Addiction follow-up before and after liver transplantation
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Hepatitis, Alcoholic
Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis
ADDUP is an observational study of patients with alcoholic hepatitis. A structured interview is used to quantitatively estimate: 1. Alcohol use 2. Dietary intake 3.
- Trial name
- ADDUP (NCT02404636)
- Testing
- Interview
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University Hospital Birmingham
Alcoholism, Cirrhosis
Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound
The purpose of this study is to determine the amount of fibrosis in the liver of hepatitis C patients with advanced fibrosis, using endoscopic ultrasound.
- Conditions
- Alcoholism, Cirrhosis, Hepatitis c
- Trial name
- NCT01208311
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Alcoholic Fatty Liver Disease, Alcoholic Hepatitis
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.
- Trial name
- NCT02019056
- Testing
- MG-1, metadoxine
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- PharmaKing
Alcohol Use Disorder, Alcoholic Liver Disease
Alcoholic Liver Disease and the Gut Microbiome
Background: Significant sex differences exist in regard to alcohol use disorder (AUD) and alcoholic liver disease (ALD). To date, no studies have examined the brain-gut-microbiome (BGM) axis (which is the relationship between the…
- Conditions
- Alcohol Use Disorder, Alcoholic Liver Disease, Microbiome
- Trial name
- NCT05007470
- Testing
- VSL #3 112.5 Capsule
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Drug Induced Liver Injury
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver.
- Trial name
- Non-Drinker (NCT00616018)
- Testing
- acetaminophen
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kennon Heard
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Severe Alcoholic Hepatitis
Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis
Severe alcoholic hepatitis, defined by a "Maddrey discriminant function" above 32, is associated with significant short-term mortality.
- Trial name
- CALPRO-HAA (NCT02808663)
- Testing
- fecal calprotectin concentration, blood collection
- Where
- France
- Volunteers
- 6 people
- Sponsor
- CHU de Reims
Liver Disease Chronic, Cirrhosis
cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit
The aim of this study is to conduct a quick assessment of potential liver damage caused by chronic alcohol consumption. Taking advantage of the patient's admission to a specialized detoxification unit, several tests will be…
- Conditions
- Liver Disease Chronic, Cirrhosis, Detoxification, Alcohol Abuse/Dependence
- Trial name
- HEP-UHD (NCT06838468)
- Testing
- Screening of compensated advance chronic liver disease
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Corporacion Parc Tauli
Liver Diseases, Alcohol Use Disorder
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
The study consists of a randomized controlled trial evaluating the efficacy and feasibility of a stepped alcohol treatment using telemedicine on unhealthy alcohol use in patients with chronic liver disease receiving care in…
- Trial name
- NCT05191446
- Testing
- Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC)
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- University of California, San Francisco
Alcoholic Liver Disease
Study of Alcohol-related Liver Disease in Europe
Alcohol-induced liver injury is made up of fatty liver, fibrosis and alcoholic hepatitis (AH), elementary lesions that may occur separately, simultaneously or sequentially in a same patient.
- Trial name
- SALVE (NCT04400604)
- Where
- France
- Volunteers
- 7,500 people
- Sponsor
- University Hospital, Lille
Alcoholic Liver Disease
Effect of Candesartan in Alcoholic Liver Fibrosis
Background: Alcohol is one of principal causes of hepatic fibrosis. Although the most effective treatment for alcoholic hepatic fibrosis is abstinence of alcohol consumption, additive treatment to reduce the accumulation of scar…
- Trial name
- NCT00990639
- Testing
- candesartan for hepatic fibrosis
- Where
- South Korea
- Volunteers
- 85 people
- Sponsor
- Yonsei University
Alcohol Use Disorder, Liver Diseases
Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are intersecting diseases that add substantially to the global burden of disease and mortality.
- Trial name
- NCT05135767
- Testing
- Brief Motivational Interviewing with Personalized Feedback
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Brown University
Alcoholic Liver Disease
Alcohol, Gut Leakiness, & Liver Disease
The goal of this study is to investigate the role of gut leakiness in alcoholic liver disease. Gut leakiness may be the missing susceptibility factor that explains why some alcoholics develop liver disease and others don't.
- Trial name
- NCT05428072
- Testing
- Sugar test, Aspirin Challenge
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Alcoholic Liver Disease
French National MICMAF Cohort
Excessive alcohol consumption is a major public health problem, particularly in France. It is the leading cause of cirrhosis and hepatocellular carcinoma.
- Trial name
- MICMAF (NCT05895890)
- Testing
- Sequential sampling (stool, saliva, serum) .
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris